Acorda Therapeutics Debuts Art Exhibition Inspired by People with Parkinson’s at the 5th World Parkinson Congress

  • Framing OFF Through Art℠ gallery illustrates individuals’
    experience with OFF periods
  • New research on OFF periods to be presented at conference plenary

ARDSLEY, N.Y.–(BUSINESS WIRE)–Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that it will
debut an art gallery inspired by people with Parkinson’s (PwP) at the 5th
World Parkinson Congress (WPC) in Kyoto, Japan. The six pieces of art,
ranging from acrylic sculptures to oil paintings, are the centerpiece of
Acorda’s Framing
OFF Through Art
initiative. OFF periods are the re-emergence of
Parkinson’s symptoms, and affect approximately 40 percent of the one
million people living with Parkinson’s in the U.S. This initiative
builds on Acorda’s “Live Well. Do Tell.℠” program; its goal is to help
initiate effective conversations about OFF periods between PwPs and
their healthcare professionals.

Framing OFF Through Art uses the power of art to help PwPs better
identify and articulate their experiences with OFF periods. It includes
a series of artworks inspired by the personal stories of people with
Parkinson’s and their care partners. The artworks were created by
artists who also have a personal connection to the disease. Conference
attendees can view the gallery and learn more at Acorda’s booth, #209.

“Research has consistently shown that OFF periods are among the most
common issues for people living with Parkinson’s disease,” said Ron
Cohen, M.D., Acorda’s President and CEO. “This re-emergence of
Parkinson’s symptoms can occur unexpectedly, up to several times a day,
despite daily medication regimens; this causes enormous disruption and
distress to the people who experience this. In addition, each person’s
experience with OFF periods is unique and can be difficult to describe.
We believe that people with Parkinson’s will be able to see aspects of
their own experiences with Parkinson’s and OFF periods in these works of
art, and use this as an opportunity to discuss their symptoms with their
healthcare team.”

In addition, new research on the nature and diversity of Parkinson’s
disease will be presented by Connie Marras, M.D., Ph.D., associate
professor at University Health Network, University of Toronto, during
the Morning Plenary on June 6, 2019, at 9:30 am JST. Dr. Marras will
also be presenting research around OFF periods during the poster tour on
June 5, 2019. The research on OFF periods was supported by an Acorda
Therapeutics research grant, administered by The Michael J. Fox
Foundation for Parkinson’s Research.

Acorda is also a gold sponsor of the WPC
2019 Art Walk
– a series of art, live music and dance exhibits. One
of these exhibits, “Soaring with Hope for PD,” features an installation
of 15,000 origami cranes with messages of hope from 39 countries.

About “Live Well. Do Tell.”

“Live Well. Do Tell.” is an initiative created by Acorda with input from
a multi-disciplinary Steering Committee of Parkinson’s community
leaders. The goal of the program is to develop tools to address
communication gaps among people with Parkinson’s, their care partners
and their healthcare professionals.

The Steering Committee included people with Parkinson’s, care partners,
movement disorder specialists, a nurse practitioner and representatives
from key advocacy groups, including the American Parkinson’s Disease
Association, Caregiver Action Network, Davis Phinney Foundation, The
Michael J. Fox Foundation, Parkinson’s Foundation, the Parkinson &
Movement Disorder Alliance and the World Parkinson Coalition.

For more information about “Live Well. Do Tell.” and Framing OFF
Through Art,

About Parkinson’s and OFF Periods

Parkinson’s is a progressive neurodegenerative disorder resulting from
the gradual loss of certain neurons. These neurons are responsible for
producing dopamine and that loss causes a range of symptoms including
impaired movement, muscle stiffness and tremors. As Parkinson’s
progresses, people are likely to experience OFF periods, which are
characterized by the return of Parkinson’s motor and non-motor symptoms;
these can occur even in the presence of regular maintenance therapy.
Approximately one million people in the U.S. and 10 million people
worldwide are living with Parkinson’s; approximately 40 percent of
people with Parkinson’s in the U.S. are estimated to experience OFF

About Acorda Therapeutics

Acorda Therapeutics develops therapies to restore function and improve
the lives of people with neurological disorders. For more information on
Acorda products and pipeline, visit:

Forward-Looking Statement

This press release includes forward-looking statements. All statements,
other than statements of historical facts, regarding management’s
expectations, beliefs, goals, plans or prospects should be considered
forward-looking. These statements are subject to risks and uncertainties
that could cause actual results to differ materially, including: we may
not be able to successfully market Inbrija or any other products under
development; risks associated with complex, regulated manufacturing
processes for pharmaceuticals, which could affect whether we have
sufficient commercial supply of Inbrija to meet market demand; third
party payers (including governmental agencies) may not reimburse for the
use of Inbrija or our other products at acceptable rates or at all and
may impose restrictive prior authorization requirements that limit or
block prescriptions; competition for Inbrija, Ampyra and other products
we may develop and market in the future, including increasing
competition and accompanying loss of revenues in the U.S. from generic
versions of Ampyra (dalfampridine) following our loss of patent
exclusivity; the ability to realize the benefits anticipated from
acquisitions, among other reasons because acquired development programs
are generally subject to all the risks inherent in the drug development
process and our knowledge of the risks specifically relevant to acquired
programs generally improves over time; we may need to raise additional
funds to finance our operations and may not be able to do so on
acceptable terms; the risk of unfavorable results from future studies of
Inbrija (levodopa inhalation powder) or from our other research and
development programs, or any other acquired or in-licensed programs; the
occurrence of adverse safety events with our products; the outcome (by
judgment or settlement) and costs of legal, administrative or regulatory
proceedings, investigations or inspections, including, without
limitation, collective, representative or class action litigation;
failure to protect our intellectual property, to defend against the
intellectual property claims of others or to obtain third party
intellectual property licenses needed for the commercialization of our
products; and failure to comply with regulatory requirements could
result in adverse action by regulatory agencies.

These and other risks are described in greater detail in our filings
with the Securities and Exchange Commission. We may not actually achieve
the goals or plans described in our forward-looking statements, and
investors should not place undue reliance on these statements.
Forward-looking statements made in this press release are made only as
of the date hereof, and we disclaim any intent or obligation to update
any forward-looking statements as a result of developments occurring
after the date of this press release.


Tierney Saccavino
(914) 326-5104

Felicia Vonella
(914) 326-5146

error: Content is protected !!